Pacitti David 4/A

What Happened
David Pacitti, Chief Executive Officer of Avanos Medical, was granted a total of 342,362 restricted share units (RSUs/TRSUs) on March 13, 2026. The filing shows two awards: 101,341 TRSUs (priced $0.00) and 241,021 derivative TRSUs (priced $0.00). These are awards under Avanos’s 2021 Long Term Incentive Plan and were reported on a Form 4/A (amendment) filed April 1, 2026. There was no cash paid — these are compensation awards, not open-market purchases.

Key Details

• Transaction date: March 13, 2026. Report filed (amended) April 1, 2026.
• Price: $0.00 per unit (award/grant). Total units: 101,341 + 241,021 = 342,362 TRSUs.
• Vesting (per footnotes):
  • 101,341 TRSUs: time‑based, vest 1/3 on Mar 13 of 2027, 2028 and 2029.
  • 241,021 TRSUs: vest 30% on Mar 13, 2027; 30% on Mar 13, 2028; 40% on Mar 13, 2029.
• Shares owned after transaction: Not specified in this filing.
• Filing status: This is an amended Form 4 (Form 4/A) filed to correct an error in the calculation of awards issued on March 13, 2026. The amendment was filed on April 1, 2026 — after the transaction date (i.e., late relative to the usual 2‑business‑day Form 4 deadline).

Context
These are compensation awards (time‑based RSUs/TRSUs), meaning they represent the economic equivalent of shares but generally are not transferable or saleable until they vest. Because these are grants (code A), they do not reflect an open‑market purchase or sale by the insider; they’re routine executive compensation. The amendment notes a correction to the originally reported quantities — investors should treat this as a clerical correction rather than a trading signal.